1stOncology™: Cancer Intelligence Service – Page 10141 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cytocom to Present at BIO CEO & Investor Digital Conference

On February 11, 2021 Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, reported that Mike Handley, President and Chief Executive Officer, will present at the BIO CEO & Investor Digital Conference taking place Tuesday, February 16, 2021 to Thursday, February 18, 2021 (Press release, Cytocom, FEB 11, 2021, https://www.cytocom.com/2021/02/11/cytocom-to-present-at-bio-ceo-investor-digital-conference/?utm_source=rss&utm_medium=rss&utm_campaign=cytocom-to-present-at-bio-ceo-investor-digital-conference [SID1234574912]). The presentation will be available on demand during the virtual event for all registered attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

During the presentation, Mr. Handley will provide an overview of Cytocom’s business and recent corporate achievements, as well as the anticipated milestones in its clinical programs for COVID-19, pancreatic cancer, Crohn’s disease, fibromyalgia and multiple sclerosis.

Details of the events are as follows:

Event: BIO CEO & Investor Digital Conference
Date: Tuesday, February 16, 2021 to Thursday, February 18, 2021
Time: Available on Demand
Registration: View Source

Members of the Cytocom’s management team will be available to participate in virtual one-on-one meetings with investors who are registered to attend the conference. Following the conclusion of the event, a recording of Mr. Handley’s presentation will be available under "Recent Presentations" in the Investors section of the Company’s website at www.cytocom.com.

Cerus Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

On February 11, 2021 Cerus Corporation (Nasdaq: CERS) reported that its fourth quarter and full year 2020 financial results will be released on Thursday, February 25, 2021, after the close of the stock market (Press release, Cerus, FEB 11, 2021, View Source [SID1234574911]). The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at View Source Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on Cerus’ website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 1267389. The replay will be available approximately three hours after the call through March 11, 2021.

GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market

On February 11, 2021 GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE) technology platform reported the pricing of an underwritten public offering of 4,300,000 Units, consisting of one share of its common stock and one warrant to purchase one share of its common stock, at a public offering price of $5.50 per Unit or Pre-Funded Unit, as applicable (Press release, GT Biopharma, FEB 11, 2021, View Source [SID1234574910]). In addition, the Company has granted the underwriters a 45-day over-allotment option to purchase up to an additional 645,000 Units, less underwriting discounts and commissions. At the option of the purchasers in the offering in certain circumstances, in lieu of issuing a Unit, the Company may issue a Pre-Funded Unit, consisting of one pre-funded warrant to acquire one share of its common stock and one warrant to purchase one share of its common stock. The offering is expected to close on February 16, 2021, subject to the satisfaction of customary closing conditions.

In connection with the offering, the Company has been approved for listing common stock on The Nasdaq Capital Market. In addition, the Company effected a 1-for-17 reverse stock split and its common stock will begin trading on The Nasdaq Capital Market under the existing ticker symbol, "GTBP" on a post-reverse stock split basis at the opening of market hours on Thursday, February 11, 2021.

Gross proceeds to the Company from the offering are expected to be approximately $23.6 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters’ over-allotment option.

Roth Capital Partners and Dawson James Securities, Inc. are acting as joint book-running managers for the offering.

The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (Registration No. 333-251311) that was previously filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective on February 10, 2021. This offering is being made only by means of a prospectus. A preliminary prospectus relating to and describing the terms of the offering has been filed with the SEC. Electronic copies of the preliminary prospectus and, when available, copies of the final prospectus relating to the offering may be obtained for free by visiting the SEC’s website at www.sec.gov, Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660, (800) 678-9147 or by contacting Dawson James Securities, Inc., Attn: Bari Latterman, Email: [email protected], Telephone: 561-208-2939.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021

On February 11, 2021 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported financial results and provide business updates for the fourth quarter and year ended December 31, 2020, before the US markets open on Thursday, February 25, 2021 (Press release, Adaptimmune, FEB 11, 2021, View Source [SID1234574907]). Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day (details below).

The press release and the live webcast of the conference call will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com. An archive will be available after the call at that same address.

To participate in the live conference call, please dial (833) 652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (2099860).

Incyte to Present at Upcoming Investor Conference

On February 11, 2021 Incyte (Nasdaq:INCY) reported that it will present at the virtual Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021 at 2:00 p.m. EST (Press release, Incyte, FEB 11, 2021, View Source [SID1234574906]).

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days.